ブリバラセタム

 ブリバラセタム 化学構造式
357336-20-0
CAS番号.
357336-20-0
化学名:
ブリバラセタム
别名:
ブリバラセタム;ブリバラセタム;ブリーバラセタム;(S)-2-(4β-プロピル-2-オキソ-1-ピロリジニル)ブタンアミド;(2S)-2-[(4R)-2-オキソ-4-プロピルピロリジン-1-イル]ブタンアミド
英語名:
Brivaracetam
英語别名:
Briviact;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;UCB 34714;UCB34714;UCB-34714;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;Boisitan;Boisetan;UCB-34714;Buvacitan
CBNumber:
CB81508592
化学式:
C11H20N2O2
分子量:
212.29
MOL File:
357336-20-0.mol

ブリバラセタム 物理性質

融点 :
76.38°
比旋光度 :
D25 -60.57° (c = 1 in methanol)
沸点 :
409.3±28.0 °C(Predicted)
比重(密度) :
1.062
貯蔵温度 :
Refrigerator
溶解性:
DMSO(微量)、メタノール(微量)
外見 :
個体
酸解離定数(Pka):
15.74±0.50(Predicted)
色:
ホワイトからオフホワイト
InChI:
InChI=1/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/s3
InChIKey:
MSYKRHVOOPPJKU-MASDURLHNA-N
SMILES:
[C@H](N1C(C[C@@H](CCC)C1)=O)(CC)C(=O)N |&1:0,4,r|
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
絵表示(GHS) GHS hazard pictograms
注意喚起語
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 GHS hazard pictograms P264, P270, P301+P312, P330, P501
注意書き
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P301+P312 飲み込んだ場合:気分が悪い時は医師に連絡する こと。
P330 口をすすぐこと。
P501 内容物/容器を...に廃棄すること。

ブリバラセタム 価格 もっと(3)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) SML3476 Brivaracetam ≥98% (HPLC)
≥98% (HPLC)
357336-20-0 10mg ¥11300 2024-03-01 購入
富士フイルム和光純薬株式会社(wako) Y0002407 Brivaracetam CRS European Pharmacopoeia (EP) Reference Standard
European Pharmacopoeia (EP) Reference Standard
357336-20-0 Y0002407 ¥77600 2024-03-01 購入
富士フイルム和光純薬株式会社(wako) SML3476 Brivaracetam ≥98% (HPLC)
≥98% (HPLC)
357336-20-0 50mg ¥45400 2024-03-01 購入

ブリバラセタム 化学特性,用途語,生産方法

効能

抗けいれん薬, 疼痛治療

説明

Brivaracetam, a novel oral antiepileptic drug with a high affinity for synaptic vesicle protein 2A (SV2A), was approved in Europe and the US as an adjunctive therapy for the treatment of partial onset seizures with or without secondary generalization in patients aged 16 or older.42 Brivaracetam is very closely related to levetiracetam, an antiepileptic treatment whose immediate release formulation has been available in the United States as a generic drug since 2008, but whose extended release formulation is under patent protection until 2028. The two drugs, which were both developed by UCB Pharma, are structurally similar with brivaracetam having an n-propyl group at the C-4 position of the pyrrolidinone ring and levetiracetam having a hydrogen at this same position. A systematic investigation of the various substitutions of levetiracetam resulted in the identification of more potent and selective SV2A ligands and ultimately culminated in the discovery of brivaracetam, which has greater affinity for SV2A, improved selectivity, more rapid brain penetration, and faster onset of action against seizures than levetiracetam.

使用

Treatment ofTreatment of epilepsy, neuropathic pain and essential tremor.

定義

ChEBI: A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.

副作用

Common side effects of brivaracetam include: constipation, nausea, vomiting, extreme tiredness or low energy. Serious side effects that may be caused include: swelling of the face, throat, tongue, lips, and eyes; difficulty swallowing or breathing; hoarseness, hallucinations (seeing things or hearing sounds that are not there), and delusions (strange thoughts or beliefs that have no basis in reality). An overdose may cause: drowsiness, extreme tiredness, dizziness, difficulty maintaining balance, blurred or double vision, slowed heartbeat, nausea, and feeling anxious.

ブリバラセタム 上流と下流の製品情報

原材料

準備製品


ブリバラセタム 生産企業

Global( 331)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Chengdu Aupone Pharmaceutical Co.Ltd.
+86-28-+86-28-87843998-6060-6060 +8618631098571
lijiaqi@aupone.com China 43 58
Lewoo Pharmatech(Shanghai)Co.,Ltd
+86-15800805830 +86-15800805830
miao@lewoopharma.com.cn China 156 58
Biopole Pharmatech Co., Ltd.
+8615151475053
biopole@163.com China 37 58
Dorne Chemical Technology co. LTD
+86-13583358881 +86-18560316533
Ethan@dornechem.com China 294 58
Firsky International Trade (Wuhan) Co., Ltd
+8615387054039
admin@firsky-cn.com China 436 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638
sales@sdperfect.com China 294 58
Wuhan Ruichi Technology Co., Ltd
+8613545065237
admin@whrchem.com China 164 58
Shandong Hanjiang Chemical Co., Ltd
+86-0533-2066820 +8618369939125
hanson@sdhanjiang.com China 1527 58
Shanghai Affida new material science and technology center
+undefined15081010295
2691956269@qq.com China 359 58
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 15928 58

357336-20-0( ブリバラセタム)キーワード:


  • 357336-20-0
  • UCB-34714
  • 2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide
  • API-Anti Epilepsy
  • brivaracetam
  • BrivaracetamL
  • 1-Pyrrolidineacetamide,a-ethyl-2-oxo-4-propyl-, (aS,4R)-
  • brivaracetam USP/EP/BP
  • Brivaracetam Impurity 43
  • Boisitan
  • Briracetam
  • Eomeprazole
  • (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide
  • 1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-
  • (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide
  • (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
  • UCB 34714;UCB34714;UCB-34714
  • Briviact
  • (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanam
  • Buvacitan
  • buvacetam
  • Boisetan
  • ブリバラセタム
  • ブリバラセタム
  • ブリーバラセタム
  • (S)-2-(4β-プロピル-2-オキソ-1-ピロリジニル)ブタンアミド
  • (2S)-2-[(4R)-2-オキソ-4-プロピルピロリジン-1-イル]ブタンアミド
Copyright 2017 © ChemicalBook. All rights reserved